Sun Pharmaceutical Industries Ltd. acquired Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.  “We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub,”...